Sagar V. Parikh
YOU?
Author Swipe
View article: The Canadian Network for Mood and Anxiety Treatments Task Force Recommendations for the Use of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplants in Adults With Major Depressive Disorder: Recommandations du Groupe de travail du Réseau canadien pour le traitement des troubles de l’humeur et de l’anxiété (Canadian Network for Mood and Anxiety Treatments, CANMAT) concernant l’utilisation des probiotiques, des prébiotiques, des symbiotiques et de la transplantation de microbiote fécal chez les adultes atteints de trouble dépressif majeur
The Canadian Network for Mood and Anxiety Treatments Task Force Recommendations for the Use of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplants in Adults With Major Depressive Disorder: Recommandations du Groupe de travail du Réseau canadien pour le traitement des troubles de l’humeur et de l’anxiété (Canadian Network for Mood and Anxiety Treatments, CANMAT) concernant l’utilisation des probiotiques, des prébiotiques, des symbiotiques et de la transplantation de microbiote fécal chez les adultes atteints de trouble dépressif majeur Open
Background Approximately one-third of adults with major depressive disorder (MDD) experience limited response or intolerable side effects with existing pharmacotherapies. As such, innovative treatments targeting novel biological pathways a…
Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With Depression Open
Purpose/Background: Multiple meta-analyses have suggested that pharmacogenomic (PGx) testing may be a valuable tool to improve clinical outcomes for patients with major depressive disorder (MDD) who have failed at least one treatment. Howe…
View article: Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer
Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer Open
The efficacy of subanesthetic intravenous ketamine for treatment resistant depression (TRD) has spurred a growth of clinics nationwide that provide this service. Ketamine is an FDA-approved drug as an anesthetic but remains unapproved for …
Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study Open
Weight gain is a common side-effect of medications used to treat major depressive disorder (MDD). We sought to estimate the frequency of weight gain for obesogenic medications prescribed for MDD and to evaluate if bupropion mitigated risk …
Impact of a Student Pharmacist Driven Medication Reconciliation and Antidepressant Treatment History Project at a Depression Clinic: A Pilot Study Open
Objectives To improve treatment of patients with depression, a new pilot service project involving student pharmacists who would conduct medication reconciliation and review of antidepressant treatment history was created and evaluated. Ex…
Psychiatric Prescribing Patterns for Depression Treatment in an Outpatient Depression Clinic Open
Objective: To elucidate psychiatric prescribing patterns for depression treatment in patients being seen by an outpatient depression clinic as of 2018. Experimental Design: Single-center, observational analysis. Principle Observation: Sele…
Integrating Patient Choice and Collaborative Care Managers to Implement eHealth Tools in Depression: Self-Report Pilot Study Open
Background Improving mental health treatment within the collaborative care model (CoCM) may be achieved by using e-mental health (e-MH) tools and addressing the challenges to their integration. Objective This study aims to understand how p…
View article: Standardized EEG for multi-site biomarker-informed trials: Implementation in the Canadian Biomarker Integration Network in Depression
Standardized EEG for multi-site biomarker-informed trials: Implementation in the Canadian Biomarker Integration Network in Depression Open
Our study offers comprehensive solutions for EEG practices across multiple sites, providing valuable insights and inspiration for establishing standardization approaches in collaborative neuroimaging efforts beyond depression research.
Development of the treatment prediction model in the artificial intelligence in depression – medication enhancement study Open
We introduce an artificial intelligence model to personalize treatment in major depression, which was deployed in the Artificial Intelligence in Depression: Medication Enhancement Study. We predict probabilities of remission across multipl…
Development of the treatment prediction model in the artificial intelligence in depression – medication enhancement study Open
INTRODUCTION: The pharmacological treatment of Major Depressive Disorder (MDD) relies on a trial-and-error approach. We introduce an artificial intelligence (AI) model aiming to personalize treatment and improve outcomes, which was deploye…
View article: High Baseline Plasma Anthranilic Acid Predicts Remission Upon Acute-Series Ketamine Infusion for Treatment-Resistant Depression
High Baseline Plasma Anthranilic Acid Predicts Remission Upon Acute-Series Ketamine Infusion for Treatment-Resistant Depression Open
Elevated AA levels and AA-based biomarker ratios predicted ketamine remission in patients with TRD, supporting biomarker-driven personalized treatment. These findings highlight immunometabolic mechanisms in ketamine response.
View article: Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1 Open
Objective The genetic architecture of antidepressant response is poorly understood. This study investigated whether polygenic risk scores (PRSs) for major psychiatric disorders and a personality trait (neuroticism) are associated with anti…
View article: Canadian Network for Mood and Anxiety Treatments 2024 Clinical Practice Guideline for the Management of Perinatal Mood, Anxiety, and Related Disorders: Guide de pratique 2024 du Canadian Network for Mood and Anxiety Treatments pour le traitement des troubles de l'humeur, des troubles anxieux et des troubles connexes périnatals
Canadian Network for Mood and Anxiety Treatments 2024 Clinical Practice Guideline for the Management of Perinatal Mood, Anxiety, and Related Disorders: Guide de pratique 2024 du Canadian Network for Mood and Anxiety Treatments pour le traitement des troubles de l'humeur, des troubles anxieux et des troubles connexes périnatals Open
Background The Canadian Network for Mood and Anxiety Treatments (CANMAT) publishes clinical practice guidelines for mood and anxiety disorders. This CANMAT guideline aims to provide comprehensive clinical guidance for the pregnancy and pos…
View article: Lam Employment Absence and Productivity Scale (LEAPS): Analysis of the minimal clinically important difference (MCID) in patients with major depressive disorder using data from the CAN-BIND-1 study
Lam Employment Absence and Productivity Scale (LEAPS): Analysis of the minimal clinically important difference (MCID) in patients with major depressive disorder using data from the CAN-BIND-1 study Open
OBJECTIVES: Major depressive disorder (MDD) is associated with significant impairment in occupational functioning. The Lam Employment Absence and Productivity Scale (LEAPS) is a self-report questionnaire validated for the assessment of wor…
TMIC-14. RAPID EARLY PROGRESSION IN GLIOBLASTOMA: A COMPREHENSIVE REVIEW OF CLINICAL, IMAGING AND HISTOPATHOLOGICAL FEATURES Open
BACKGROUND In glioblastoma patients, Rapid Early Progression (REP) refers to tumour growth between the time of surgery and postoperative chemoradiotherapy. Despite its high incidence relatively little is known about it. The aim of this stu…
Electroencephalography Markers of Perinatal Depression and Anxiety in a Diverse Longitudinal Cohort: A Preliminary Study Open
Perinatal mental health disorders, such as depression and anxiety, are highly prevalent and can have severe consequences on maternal morbidity and mortality, and on infant neurodevelopment. Yet, the biological mechanisms of these disorders…
Familiarity with Psychiatric Pharmacogenomic Testing in Physicians and Advanced Practice Providers: Educational Opportunities Open
Introduction Pharmacogenomic (PGx) testing identifies individual genetic variation that may inform medication treatment. Lack of awareness and education may be barriers to implementing routine PGx testing. To characterize current PGx testi…
Development and Validation of a Deep-Learning Model for Differential Treatment Benefit Prediction for Adults with Major Depressive Disorder Deployed in the Artificial Intelligence in Depression – Medication Enhancement (AID-ME) Study Open
We introduce an artificial intelligence (AI) model aiming to personalize treatment in adult major depression, which was deployed in the Artificial Intelligence in Depression: Medication Enhancement (AID-ME) Study. Our objectives were to pr…
View article: Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Deep Learning Enabled Clinical Decision Support System for Personalized Depression Treatment Selection and Management
Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Deep Learning Enabled Clinical Decision Support System for Personalized Depression Treatment Selection and Management Open
Major Depressive Disorder (MDD) is a leading cause of disability and there is a paucity of tools to personalize and manage treatments. A cluster-randomized, patient-and-rater-blinded, clinician-partially-blinded study was conducted to asse…
View article: Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Deep Learning Enabled Clinical Decision Support System for Personalized Depression Treatment Selection and Management
Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Deep Learning Enabled Clinical Decision Support System for Personalized Depression Treatment Selection and Management Open
Background There has been increasing interest in the use of Artificial Intelligence (AI)-enabled clinical decision support systems (CDSS) for the personalization of major depressive disorder (MDD) treatment selection and management, but cl…
Large Individual Differences in Functional Connectivity in the Context of Major Depression and Antidepressant Pharmacotherapy Open
Clinical studies of major depression (MD) generally focus on group effects, yet interindividual differences in brain function are increasingly recognized as important and may even impact effect sizes related to group effects. Here, we exam…
View article: Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes Open
Background The Canadian Network for Mood and Anxiety Treatments (CANMAT) last published clinical guidelines for the management of major depressive disorder (MDD) in 2016. Owing to advances in the field, an update was needed to incorporate …
Long-term safety and frequency of repeat zuranolone treatment in patients with major depressive disorder rolling over from the randomised CORAL Study into the open-label SHORELINE Study Open
Introduction Zuranolone (ZRN) is a positive allosteric modulator of both synaptic and extrasynaptic gamma-aminobutyric acid type A receptors and a neuroactive steroid approved as an oral, once-daily, 14-day treatment course for adults with…
Correction: Evaluating the Clinical Feasibility of an Artificial Intelligence–Powered, Web-Based Clinical Decision Support System for the Treatment of Depression in Adults: Longitudinal Feasibility Study Open
[This corrects the article DOI: 10.2196/31862.].
Correction: Evaluating the Clinical Feasibility of an Artificial Intelligence–Powered, Web-Based Clinical Decision Support System for the Treatment of Depression in Adults: Longitudinal Feasibility Study (Preprint) Open
UNSTRUCTURED